Solarea Bio is a preclinical-stage biotechnology company in Cambridge, MA developing new microbiome-based solutions to some of the world’s largest health problems. Solarea was founded in 2017 by a group of scientists and entrepreneurs eager to radically alter our understanding of the human microbiome and utilize its power to improve human health. The Solarea breakthrough came from the combined efforts of the company’s co-founders who established a link between the discovery of an untapped source of microorganisms with probiotic potential in healthy foods, and their applications in inflammatory processes including the gut-musculoskeletal axis. Using powerful genomic and bioinformatic tools, Solarea is mining its novel microbial strain collection to identify synergistic combinations of microbes and prebiotic plant fibers to develop solutions for patients suffering from inflammatory processes.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $26.2M
Founded date: 2017
Investors 3
| Date | Name | Website |
| - | Joyance Pa... | joyancepar... |
| - | S2G Ventur... | s2gventure... |
| - | Tencent | tenx.tc |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 17.05.2023 | Series B | $15M | Bold Capit... |
| 19.10.2020 | Series A | $11.2M | - |
Mentions in press and media 15
| Date | Title | Description |
| 14.02.2025 | Future Food-Tech San Francisco 2025: 61 Startups to Showcase the Future of Food | The upcoming Future Food-Tech Summit, set to take place in San Francisco on March 13-14, 2025, will feature 61 startups and scale-ups presenting innovations in food technology. The event, recognized as a hub for investment and collaboration... |
| 26.06.2024 | Ilissa Larimore Appointed Chief Commercial Officer at Solarea Bio | BOSTON, June 26, 2024 /PRNewswire/ -- Solarea Bio, a pioneering biotechnology company focused on developing solutions to improve human health by harnessing the edible plant microbiome, announces the appointment of Ilissa Larimore as Chief C... |
| 08.05.2024 | Solarea Bio Announces the Beta Launch of Bondia™, a Novel Daily Medical Food Helping Menopausal Women Manage Bone Loss | The complete beta launch experience, known as the Beta Complete Journey, includes a baseline total body DEXA scan, a year of Bondia™ capsules, and access to an accompanying mobile app. BOSTON, May 8, 2024 /PRNewswire/ -- All peri- and postm... |
| 17.05.2023 | Solarea Bio Raises $15M, Gingko Joins Partnership, and More Boston Tech News Jobs from companies in this blog | Photo: Shutterstock Biotech has long been a bustling sector in the Bay State, with universities, research institutions and startups alike attracting technology and life sciences talent from across the globe. This past week saw several major... |
| 08.05.2023 | Solarea Bio Announces $15M in Series B Financing | CAMBRIDGE, MA, Solarea Bio,announced first closing of $15M in Series B financing. >> Click here for more funding data on Solarea Bio >> To export Solarea Bio funding data to PDF and Excel, click here Solarea Bio, a clinic... |
| 08.05.2023 | Solarea Bio Holds First $15M Close of Series B Financing | Solarea Bio, a Cambridge, MA-based clinical stage biotechnology company, raised $15M in Series B funding. The round was led by S2G Ventures with participation from Bold Capital Partners, Viking Global Investors, and GG 1978 SICAF SIF. A tot... |
| 02.10.2022 | The Motivation Behind our Microbiome Focus | Photo by CDC on Unsplash Scientific exploration of the microbiome represents the opening of one of the greatest areas of science in decades, perhaps centuries. The biome utterly defines novel new approaches to the prevention and treatment ... |
| 19.10.2021 | Solarea Bio : Announces Licensing Agreement with ADM | CAMBRIDGE, Mass., Oct. 19, 2021 /PRNewswire/ -- Solarea Bio, a biotech company based in Cambridge, MA that is developing microbial-based solutions to aid human health, today announced it has signed a technology licensing agreement with glob... |
| 19.10.2020 | Solarea Bio Announces Series A Financing Led by S2G Ventures and Bold Capital Partners | |
| 19.10.2020 | Solarea Bio Raises $11.2M in Series A Financing | Solarea Bio, a Cambridge, MA-based biotech company developing microbial-based solutions to aid human health, raised $11.2M in Series A financing. The round was led by S2G Ventures and Bold Capital Partners, with participation from Viking Gl... |
Show more